Compound Profiling und Screening
The skin and mucosa of all humans are colonized by a large number of different microorganisms. Among them are opportunistic pathogens, which switch from harmless commensal organisms into life-threatening pathogens in particular when the immune system is compromised, e.g. as consequence of a severe disease or of therapeutic interventions, such as chemotherapies or antibiotic treatment. Thus, these infections frequently develop on top of another severe disease causing complications and extended stays in critical care units of hospitals. To avoid the outbreak of those infections, antibiotics are prophylactically applied, which supports the emergence of antibiotic resistance. Hence, new therapeutic approaches are urgently needed.
Prof Dr Ursula Bilitewski
In order to develop therapies for fighting infections caused by new pathogens or resistant microorganisms not only we need new drugs but, more importantly, we need to identify new targets for these drugs to act on.
Ursula Bilitewski studied chemistry at the University of Münster, earning her Ph.D. at the Institute of Physical Chemistry. After spending another year at Münster as a post-doc, she moved to Braunschweig in 1988, where she became part of the HZI – which at that time was called the GBF.
In 1994, she habilitated in biochemistry at the Technische Universität Braunschweig and, since 2002, is an adjunct professor for biochemistry. Her initial research focus, which was on establishing microscale bioanalytical systems, has since shifted to natural product research. Her work concentrates on molecular mechanisms and on identifying potential drug targets.
Since 2009, Bilitewski is head of HZI’s Biological Systems Analysis research group.
Contact data and publications of Prof. Dr. Ursula Bilitewski